Improving vaccines against tuberculosis

Immunology and Cell Biology

Volumn 81, Issue 1, 2003, Pages 34-45

  Britton, Warwick J ^a,b   Palendira, Umaimainthan ^a  

^a CENTENARY INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

DNA immunization; Mycobacterium tuberculosis; Prime boost; Subunit vaccines

Indexed keywords

ANTIGEN; BCG VACCINE; CYTOKINE; DNA VACCINE; EPITOPE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; LIVE VACCINE; NEW DRUG; SUBUNIT VACCINE; VIRULENCE FACTOR;

ANTIGEN PRESENTING CELL; BACTERIAL GENETICS; BCG VACCINATION; DRUG EFFICACY; DRUG TARGETING; GENE DELETION; GENETIC MANIPULATION; HUMAN; IMMUNE DEFICIENCY; IMMUNITY; MORTALITY; MUTAGENESIS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; TUBERCULOSIS;

HUMANS; LUNG; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; VACCINES, ATTENUATED; VACCINES, DNA; VACCINES, SUBUNIT;

ACTINOBACTERIA (CLASS); BACTERIA (MICROORGANISMS); HARNESS; MYCOBACTERIUM; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; UNCULTURED ACTINOMYCETE;

EID: 0037324244     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0818-9641.2002.01143.x     Document Type: Review

References (75)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282: 677-86.
2. Zumla A, Malon P, Henderson J, Grange JM. Impact of HIV on tuberculosis. Postgrad. Med. J. 2000; 76: 259-68.
3. Espinal MA, Laszlo A, Simonsen L et al. Global trends in resistance to antituberculosis drugs. N. Eng. J. Med. 2002; 344: 1294-303.
4. Dye C, Watt CJ, Bleed D. Low access to a highly effective therapy: a challenge for international tuberculosis control. Bull. World Health Organ. 2002; 80: 437-44.
5. Colditz GA, Brewer TF, Berkey CS et al. Efficacy of BCG vaccine in the prevention of tuberculosis. J. Am. Med. Assoc. 1994; 271: 698-702.
6. Kristensen I, Aaby P, Jensen H. Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa. BMJ 2000; 321: 1435-8.
7. Fine PE, Small PM. Exogenous reinfection in tuberculosis. N. Eng. J. Med. 1999; 341: 1226-7.
8. Britton WJ, Roche PW, Winter N. Mechanisms of persistence of mycobacteria. Trends Microbiol. 1994; 2: 284-8.
9. Feng CG, Palendira U, Groat NL, Briscoe H, Bean AGD, Britton WJ. Up-regulation of VCAM-1 and differential expansion of b integrin expressing T lymphocytes is associated with immunity to pulmonary Mycobacterium tuberculosis infection. J. Immunol. 2000; 164: 4853-60.
10. Palendira U, Bean AGD, Feng CG, Britton WJ. Lymphocyte recruitment and protective efficacy against pulmonary mycobacterial infection are independent of the route of prior Mycobacterium bovis BCG immunization. Infect. Immun. 2002; 70: 1410-16.
11. Flynn JL, Chan J. Immunology of tuberculosis. Annu. Rev. Immunol. 2001; 19: 93-129.
12. Demangel C, Britton WJ. Interaction of dendritic cells with mycobacteria: where the action starts. Immunol. Cell Biol. 2000; 78: 318-24.
13. Demangel C, Bean AGD, Feng CG, Britton WJ. Autocrine IL-10 impairs dendritic cell (DC) -derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL-12 production. Eur. J. Immunol. 2002; 32: 994-1002.
14. Demangel C, Bean AGD, Martin E, Feng CG, Kamath AT, Britton WJ. Protection against aerosol Mycobacterium tuberculosis infection using Bacille Calmette-Guérin (BCG) infected dendritic cells. Eur. J. Immunol. 1999; 29: 1972-9.
15. Casanova J-L, Abel L. Genetic dissection of immunity to mycobacteria: The human model. Annu. Rev. Immunol. 2002; 20: 581-620.
16. Roach DR, Briscoe H, Saunders BM, France MP, Riminton S, Britton WJ. Secreted lymphotoxin-alpha is essential for the control of intracellular bacterial infection, J. Exp. Med. 2001; 193: 239-46.
17. Cooke GS, Hill AV. Genetics of susceptibility to human infectious disease. Nat. Rev. Genet. 2001; 2: 967-77.
18. Jepson A, Fowler A, Banya W et al. Genetic regulation of acquired immune responses to antigens of Mycobacterium tuberculosis: a study of twins in West Africa. Infect. Immun, 2001; 69: 3989-94.
19. Lietman T, Blower SM. Potential impact of tuberculosis vaccines as epidemic control agents. Clin. Infect. Dis. 2000; 30: S316-22.
20. Fine PEM. Variation in protection by BCG, implications of and for heterologous immunity. Lancet 1995; 346: 1339-45.
21. Brandt L, Cunha JF, Olsen AW et al. Failure of the Mycobacterium bovis BCG vaccine: Some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immun. 2002; 70: 672-8.
22. Buddle BM, Wards BJ, Aldwell FE, Collins DM, de Lisle GW. Influence of sensitisation to environmental mycobacteria on subsequent vaccination against bovine tuberculosis. Vaccine 2002; 20: 1126-33.
23. Dockerell HM, Stoker NG, Lee SP et al. T-cell recognition of the 18-kilodalton antigen of. M. Leprae. Infect. Immun. 1989; 57: 1979-83.
24. Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from complete geneome sequence. Nature 1998; 393: 537-44.
25. Gordon SV, Brosch R, Billault A et al. Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Mol. Microbiol. 1999; 32: 643-55.
26. Triccas JA, Gicquel B. Life on the inside: probing Mycobacterium tuberculosis gene expression during infection. Immunol. Cell Biol. 2000; 78: 311-17.
27. Hondalus MK, Bardarov S, Russell R, Chan J, Jacobs WR, Bloom BR. Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis. Infect. Immun. 2000; 68: 2888-98.
28. Jackson M, Phalen SW, Lagranderie M et al. Persistence and protective efficacy of a Mycobacterium tuberculosis auxotroph vaccine. Infect. Immun. 1999; 67: 2867-73.
29. Smith DA, Parish T, Stoker NG, Bancroft GJ. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect. Immun. 2001; 69: 1142-50.
30. Sambandamurthy VK, Wang X, Chert B et al. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat. Med. 2002; 8: 1171-4.
31. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDA major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl Acad. Sci. USA 2000; 97: 13 853-8.
32. Hess J, Miko D, Catic A, Lehmensiek V, Russell DG, Kaufmann SHE. Mycobacterium bovis bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc. Natl Acad. Sci. USA 1998; 95: 5299-304.
33. Murray PJ, Aldovini A, Young RA. Manipulation and potentiation of anti-mycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines. Proc. Natl Acad. Sci. USA 1996; 93: 934-9.
34. Marshall BG, Wangoo A, O'Gaora P, Cook HT, Shaw RJ, Young DB. Enhanced anti-mycobacterial response to recombinant Mycobacterium bovis BCG expressing latency-associated peptide. Infect. Immun. 2001; 69: 6676-82.
35. Roche PW, Peake P, Fifis T, Billman-Jacobe H, Doran T, Britton WJ. T cell determinants and antibody binding sites on the major secretory protein MPB59 of Mycobacterium bovis. Infect. Immun. 1994; 62: 5319-26.
36. Andersen P, Andersen AB, Sorensen AL, Nagai S. Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice. J. Immunol. 1995; 154: 3359-72.
37. Olsen AW, van Pinxteren LAH, Okkels LM, Rasmussen PB, Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Infect. Immun. 2001; 69: 2773-8.
38. Hubbard RD, Florey CM, Collins FM. Immunization of mice with mycobacterial culture filtrate proteins. Clin. Exp. Immunol. 1992; 87: 94-8.
39. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infections with a soluble mixture of secreted antigens. Infect. Immun. 1994; 62: 2536-44.
40. Baldwin SL, Dsouza C, Roberts AD et al. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect. Immun. 1998; 66: 295 1-9.
41. Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect. Immun. 2000; 68: 791-5.
42. Coler RN, Campos-Neto A, Ovendale PJ et al. Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis, J. Immunol. 2001; 166: 6227-35.
43. Tanghe A, D'Souza S, Rosseels V et al. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect. Immun. 2001; 69: 3041-7.
44. Skeiky YA, Ovendale PJ, Jen S et al. T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J. Immunol. 2000; 165: 7140-9.
45. Huygen K, Content J, Denis O et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nature Med. 1996; 2: 893-8.
46. Kamath AT, Feng CG, Macdonald M, Briscoe H, Britton WJ. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis, Infect. Immun. 1999; 67: 1702-7.
47. Morris S, Kelley C, Howard A, Li Z, Collins F. The immunogenicity of single and combination DNA vaccines against tuberculosis. Vaccine 2000; 18: 2155-63.
48. Lowrie DB, Silva CL, Colston MJ, Ragno S, Tascon RE. Protection against tuberculosis by a plasmid DNA vaccine. Vaccine 1997; 15: 834-8.
49. Li Z, Howard A, Kelley C, Delogu G, Collins F, Morris S. Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infect. Immun. 1999; 67: 4780-6.
50. Zhu X, Venkataprasad N, Thangaraj HS et al. Functions and specificity of T cells following nucleic acid vaccination of mice against Mycobacterium tuberculosis infection. J. Immunol. 1997; 158: 5921-6.
51. Tanghe A, Lefevre P, Denis O et al. Immunogenicity and protective efficacy of tuberculosis DNA vaccines encoding putative phosphate transport receptors, J. Immunol. 1999; 162: 1113-19.
52. Jones HA, Perry RD, Dillon DC. Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect. Immunol. 1999; 67: 3879-92.
53. Tascon RE, Colston MJ, Ragno S, Stavropoulos E, Gregory D, Lowrie DB. Vaccination against tuberculosis by DNA injection. Nat. Med. 1996; 8: 888-92.
54. Delogu G, Brennan MJ. Comparative immune response to PE and PE_PGRS antigens of Mycobacterium tuberculosis. Infect. Immun. 2001; 69: 5606-11.
55. Kamath AT, Groat NL, Bean AG, Britton WJ. Protective effect of DNA immunization against mycobacterial infection is associated with the early emergence of interferon-gamma (IFN-gamma) -secreting lymphocytes. Clin. Exp. Immunol. 2000; 120: 476-82.
56. Lowrie DB, Silva CL. Enhancement of immunocompetence in tuberculosis by DNA vaccination. Vaccine 2000; 18: 1712-16.
57. Palendira U, Kamath AT, Feng CG, Britton WJ. Co-expression of Interleukin-12 chains by a self splicing vector increases the protective cellular immune response of DNA and BCG vaccines against Mycobacterium tuberculosis. Infect. Immun. 2002; 70: 1949-56.
58. Triccas JA, Sun L, Palendira U, Britton WJ. Comparative affects of plasmid-encoded interleukin 12 and interleukin 18 on the protective efficacy of DNA vaccination against Mycobacterium tuberculosis. Immunol. Cell Biol. 2002; 80: 358-63.
59. Kamath AT, Hanke T, Briscoe H, Britton WJ. Co-immunisation with DNA vaccines expressing granulocyte-macrophage colony stimulating factor and mycobacterial secreted proteins enhances T-cell immunity, but not protective efficacy against tuberculosis. Immunology 1999; 96: 511-16.
60. Delogu G, Li A, Repique C, Collins F, Morris S. DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis. Infect. Immun. 2002; 70: 292-302.
61. D'Souza S, Rosseels V, Denis O et al. Improved tuberculosis DNA vaccines by formulation in cationic lipids. Infect. Immun. 2002; 70: 3681-8.
62. Martin E, Kamath AT, Triccas JA, Britton WJ. Protection against virulent Mycobacterium avium infection following DNA vaccination with the 35 kDa antigen is accompanied by induction of 1FN-γ secreting CD4+ T cells. Infect. Immun. 2000; 68: 3090-6.
63. Martin E, Roche PW, Triccas JA, Britton WJ. DNA encoding a single mycobacterial antigen protects against leprosy infection. Vaccine 2001; 19: 1391-6.
64. Tanghe A, Content J, Van Vooren JP, Portaels F, Huygen K. Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer. Infect. Immun. 2001; 69: 5403-11.
65. Turner OC, Roberts AD, Frank AA et al. Lack of protection in mice and necrotizing bronchointerstitial pneumonia with bronchiolitis in guinea pigs immunized with vaccines directed against the hsp60 molecule of Mycobacterium tuberculosis. Infect. Immun. 2000; 68: 3674-9.
66. Cooper AM, Kipnis A, Turner J, Magram J, Ferrante J, Orme IM. Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present. J. Immunol. 2002; 168: 1322-7.
67. Feng CG, Palendira U, Demangel C, Spratt J, Malin AS, Britton WJ. Priming by DNA immunization augments the protective efficacy of Mycobacterium bovis Bacille Calmette-Guérin against tuberculosis. Infect. Immun. 2001; 69: 4174-6.
68. McShane H, Brookes R, Gilbert SC, Hill AV. Enhanced immunogenicity of CD4 (+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect. Immun. 2001; 69: 681-6.
69. Schneider J, Gilbert SC, Blanchard TJ et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 1998; 4: 397-402.
70. Kent SJ, Zhao A, Best SJ, Chandler JD, Boyle DB, Ramshaw IA. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 1998; 72: 10 180-8.
71. Feng CG, Blanchard TJ, Smith GL, Hill AVS, Britton WJ. Induction of CD8+ lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus. Immunol. Cell Biol. 2001; 79: 569-75.
72. Karonga Vaccine Trial. Trial of BCG vaccine for protection against tuberculosis and leprosy in Karonga District, Malawi. Lancet 1996; 348: 17-24.
73. Behr MA, Wilson MA, Gill WP et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999; 284: 1520-3.
74. Young DB, Stewart GR. Tuberculosis vaccines. Br. Med. Bull. 2002; 62: 73-86.
75. Kampmann B, Gaora PO, Snewin VA, Gares MP, Young DB, Levin M. Evaluation of human antimycobacterial immunity using recombinant reporter mycobacteria, J. Infect. Dis. 2002; 182: 895-901.